Compare MRAM & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRAM | WHWK |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | United States | United States |
| Employees | N/A | 22 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 202.3M | 179.8M |
| IPO Year | 2016 | N/A |
| Metric | MRAM | WHWK |
|---|---|---|
| Price | $9.75 | $3.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $14.00 | $7.00 |
| AVG Volume (30 Days) | ★ 270.2K | 175.2K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $49,417,000.00 | N/A |
| Revenue This Year | $10.22 | N/A |
| Revenue Next Year | $7.38 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 37.51 | N/A |
| 52 Week Low | $4.68 | $1.39 |
| 52 Week High | $17.24 | $4.40 |
| Indicator | MRAM | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 52.24 | 48.25 |
| Support Level | $8.40 | $1.84 |
| Resistance Level | $9.81 | $3.77 |
| Average True Range (ATR) | 0.54 | 0.23 |
| MACD | 0.15 | -0.04 |
| Stochastic Oscillator | 88.55 | 36.54 |
Everspin Technologies Inc is a manufacturer of Magnetoresistive Random Access Memory (MRAM) technology. The company manufactures MRAM products using both captive and third-party manufacturing capabilities. It purchases industry-standard complementary metal-oxide semiconductor (CMOS) wafers from semiconductor foundries and perform back end of line (BEOL) processing that includes magnetic-bit technology at leased 200mm fabrication facility in Chandler, Arizona. It also manufactures full-flow 300mm CMOS wafers with STT-MRAM magnetic-bit technology integrated in BEOL. The company's customers are in key markets, such as industrial, medical, automotive/transportation, aerospace, and data center.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.